Drug intelligence / Profile preview

PA-111A

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

PA-111A is a **small molecule drug** under development by Addpharma for the treatment of **dyslipidemias**, a group of disorders characterized by abnormal levels of lipids in the blood. The drug is currently in **Phase 1 clinical trials**. Its specific mechanism of action and molecular target have not been publicly disclosed, but it is being evaluated for pharmacokinetics and safety compared to PA-111 in healthy adults. The primary therapeutic area is endocrinology and metabolic diseases[1][5][7].

Beyond the preview

Go deeper on PA-111A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PA-111A.

Explore the full profile